Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin and Paclitaxel in Advanced Malignancies
NCT01325441Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Apr 2011
- Primary completion
- Jun 2021
- Countries
- 2
01
Overview
A Phase 2 trial of napabucasin in ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), melanoma, gastric cancer (GC), sponsored by Sumitomo Pharma America. Started Apr 2011; status: completed.
02
Drugs
napabucasin
03
Conditions
ovarian cancerbreast cancernon-small cell lung cancer (NSCLC)melanomagastric cancer (GC)
Beyond the preview
Go deeper on NCT01325441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01325441.